65,437 trials
HIV-1 Infection
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 (FDA Snapshot Analysis) — 93.7; 89.9 percentage of participants
Vitamin D Supplementation
Primary: Baseline 25 Hydroxy Vitamin D (25OHD) Levels — 28.1; 29 ng/ml
Hepatitis C, Chronic
Primary: The Percentage of Participants Achieving a Sustained Virologic Response (SVR) 24 Weeks After the Last Dose of Study Drug (SVR24 Actual) — 34.4; 72.7; 81.5; 44.4…
Huntington Disease
Primary: Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [LOCF Imputation Method] — 1.55; 1.15 units on a scale
Eyes Dry Chronic
Primary: Visual Analog Scale (VAS) Global Ocular Discomfort Score, Area Under the Curve, Day 0 to Day 28 — 63.8773; 70.2194 Units on a scale x days
Generalized Anxiety Disorder
Primary: Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1 — 25.8; 24.9; 24.4; -7.7 units on a scale
Primary Prevention of Sudden Cardiac Arrest
Primary: Inappropriate ICD Therapy — 105; 21; 26 participants — p=<0.001
Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 · Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 · Stage III Nasopharyngeal Undifferentiated Carcinoma AJCC v7
Primary: Percentage of Patients With a Grade 4 Hemorrhage or Any Grade 5 Adverse Event Assessed to be Definitely, Probably, or Possibly Related to Protocol Treatment During the…
Postoperative Complications · Memory Disorders
Primary: The Number of Cerebral Emboli During Surgery as Measured by Transcranial Doppler (TCD) — 0; 3 emboli
HIV · Hepatitis
Primary: Any Sex Risk — 48; 62; 119; 179 participants
Seasonal Influenza · Vaccine
Primary: Number of Subjects Who Reported At Least One Reactogenicity Sign After One Vaccination of TIV or cTIV — 1; 2; 204; 488 Subjects
Schizophrenia
Primary: Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 8 — 5.85; 7.28; 28.4; 12.1 ng/ml
Pancreatic Cancer
Primary: Objective Response of Tumor by RECIST 1.0 Criteria — 10; 20; 3 participants
Lesch-Nyhan Disease
Primary: Number of Participants With Clinically Significant Changes in Standard Laboratory Tests — 0 Participants
Healthy
Primary: Galactorrhea — 0; 56 percentage of participants